In 2023, Pfizer published research papers successively, reporting the results of randomized clinical trials on the efficacy and safety of PF-06882961 for blood sugar control in patients with type 2 diabetes, the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-06882961 in Japanese adults with type 2 diabetes from a phase 1 clinical trial, and the results of a 12-week randomized, placebo-controlled, dose-escalation phase 2 trial on the tolerability, safety, and pharmacodynamics of PF-06882961 for the treatment of type 2 diabetes
(2025) Funding This work was funded by the National Natural Science Foundation of China (Grant No.82371427, Grant No.82401656) and Natural Science Foundation of Chongqing, China (CSTB2024NSCQ-MSX0332, CSTB2023NSCQ-MSX0323, CSTB2023NSCQ-BHX0018)
Gastrointestinal Effects The most commonly reported adverse effects are gastrointestinal in nature, including: Nausea and vomiting (affecting 20-40% of patients initially, varying by agent and dose) [8] Diarrhoea or constipation Abdominal discomfort and bloating Reduced appetite In elderly patients, persistent nausea and vomiting can lead to dehydration and electrolyte imbalances more rapidly than in younger adults
That strategy underpins Lose For Keeps, the companys new campaign fronted by actor Rebel Wilson
